EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Effect of CYP3A5 genotypes on pharmacokinetic of tacrolimus in colombian liver transplant patients

Erica Fernanda Lindarte, Gonzalo De Jesus Vasquez, Luis Guillermo Toro Rendón, Andrés Felipe Zuluaga Salazar, Jefferson Antonio Buendia

Frontiers in Pharmacology · 11.03.2025 · 16

DOI: 10.3389/fphar.2025.1505490 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 11.03.2025. Verfasst von Erica Fernanda Lindarte und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Toxicology, Research Group in Pharmacology and Toxicology "INFARTO", University of Antioquia, Medellin, Colombia. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Previous studies have reported a reduced tacrolimus dose-adjusted exposure in individuals expressing the CYP3A5*1 allele (rs 776746). However, information regarding Colombian liver transplantation patients is scarce. This study aimed to investigate the influence of CYP3A5 polymorphism on tacrolimus (TAC) pharmacokinetics in Colombian liver transplant patients.

Methods

This was a prospective, single-center, open-label, pharmacogenetic study in stable adult liver transplant recipients followed up between 2020 and 2022. To evaluate the longitudinal relationship between the Co/doses, dose, and Co and CYP3A5 polymorphisms, a generalized estimating equations model was used using a log-gamma distribution.

Results

We evaluated 16 patients who received TAC during the first 2 years after transplantation. CYP3A5*1 expression was observed 28% of patients. Patients with CYP3A5 expressors displayed lower C0 and C0/dose ratio and higher doses than those no expressors. We observed a lower C0/dose ratio in expresser recipients over 2 years of follow-up.

Conclusion

The expression of CYP3A5 in stable liver transplant patient appeared to have the greatest influence on tacrolimus pharmacokinetics over the first 2 years posttransplant.

Schlagwörter

Stichwörter der Autor:innen

CYP3A5 polymorphismsColombialiver transplantpharmacogenenomics and personalised medicinetacrolimus

Autor:innen und Institutionen

  • Department of Pharmacology and Toxicology, Research Group in Pharmacology and Toxicology "INFARTO", University of Antioquia, Medellin, Colombia.
  • Laboratorio Integrado de Medicina Especializada (LIME), Facultad de Medicina, IPS Universitaria, Universidad de Antioquia, Antioquia, Colombia.
  • Grupo de Investigation en Genetica Medica, University of Antioquia, Medellin, Colombia.
  • Unidad de Trasplantes y Enfermedades Digestivas, Hospital San Vicente Fundación, Rionegro, Colombia.

Zitieren

APA

Lindarte, E. F., De Jesus Vasquez, G., Toro Rendón, L. G., Zuluaga Salazar, A. F., & Buendia, J. A. (2025). Effect of CYP3A5 genotypes on pharmacokinetic of tacrolimus in colombian liver transplant patients. Frontiers in Pharmacology, 16. https://doi.org/10.3389/fphar.2025.1505490

Vancouver

Lindarte EF, De Jesus Vasquez G, Toro Rendón LG, Zuluaga Salazar AF, Buendia JA. Effect of CYP3A5 genotypes on pharmacokinetic of tacrolimus in colombian liver transplant patients. Frontiers in Pharmacology. 2025;16. doi:10.3389/fphar.2025.1505490

BibTeX
@article{Lindarte2025,
  author = {Lindarte, Erica Fernanda and De Jesus Vasquez, Gonzalo and Toro Rendón, Luis Guillermo and Zuluaga Salazar, Andrés Felipe and Buendia, Jefferson Antonio},
  title = {Effect of CYP3A5 genotypes on pharmacokinetic of tacrolimus in colombian liver transplant patients},
  journal = {Frontiers in Pharmacology},
  year = {2025},
  volume = {16},
  doi = {10.3389/fphar.2025.1505490}
}
Kostenlos starten →